Catalyst Pharmaceuticals, Inc.

Symbol: CPRX

NASDAQ

15.65

USD

Market price today

  • 28.0728

    P/E Ratio

  • -0.7720

    PEG Ratio

  • 1.84B

    MRK Cap

  • 0.00%

    DIV Yield

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.85%

Operating Profit Margin

0.19%

Net Profit Margin

0.16%

Return on Assets

0.10%

Return on Equity

0.16%

Return on Capital Employed

0.14%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Richard John Daly M.B.A.
Full-time employees:167
City:Coral Gables
Address:355 Alhambra Circle
IPO:2006-11-08
CIK:0001369568

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

General Outlook

When we look at how much money they make before expenses, they keep 0.845% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.190%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.158%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.101% return, is a testament to Catalyst Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Catalyst Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.156%. Furthermore, the proficiency of Catalyst Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable 0.138% return on capital employed.

Stock Prices

Catalyst Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $15.52, while its low point bottomed out at $14.97. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Catalyst Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing CPRX liquidity ratios reveals its financial health of the firm. The current ratio of 508.51% gauges short-term asset coverage for liabilities. The quick ratio (466.16%) assesses immediate liquidity, while the cash ratio (390.13%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio508.51%
Quick Ratio466.16%
Cash Ratio390.13%

Profitability Ratios

CPRX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 20.98% underscores its earnings before tax deductions. The effective tax rate stands at 24.53%, revealing its tax efficiency. The net income per EBT, 75.47%, and the EBT per EBIT, 110.16%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 19.04%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin20.98%
Effective Tax Rate24.53%
Net Income per EBT75.47%
EBT per EBIT110.16%
EBIT per Revenue19.04%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.09, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 4 cash conversion cycle and 679.99% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding466
Days of Inventory Outstanding115
Operating Cycle168.19
Days of Payables Outstanding59
Cash Conversion Cycle109
Receivables Turnover6.80
Payables Turnover6.20
Inventory Turnover3.19
Fixed Asset Turnover109.75
Asset Turnover0.64

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.40, and free cash flow per share, 0.41, depict cash generation on a per-share basis. The cash per share value, 2.66, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.40, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.40
Free Cash Flow per Share0.41
Cash per Share2.66
Operating Cash Flow Sales Ratio0.40
Free Cash Flow to Operating Cash Flow Ratio0.29
Cash Flow Coverage Ratio52.88
Capital Expenditure Coverage Ratio1.41
Dividend Paid and Capex Coverage Ratio1.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.48%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.55%, and total debt to capitalization, 0.55%, ratios shed light on its capital structure. An interest coverage of 45.97 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.48%
Debt Equity Ratio0.01
Long Term Debt to Capitalization0.55%
Total Debt to Capitalization0.55%
Interest Coverage45.97
Cash Flow to Debt Ratio52.88
Company Equity Multiplier1.15

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.75, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.67, reflects the portion of profit attributed to each share. The book value per share, 3.65, represents the net asset value distributed per share, while the tangible book value per share, 1.82, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.75
Net Income Per Share0.67
Book Value Per Share3.65
Tangible Book Value Per Share1.82
Shareholders Equity Per Share3.65
Interest Debt Per Share0.03
Capex Per Share-1.87

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 85.90%, indicates top-line expansion, while the gross profit growth, 92.56%, reveals profitability trends. EBIT growth, -14.75%, and operating income growth, -14.75%, offer insights into operational profitability progression. The net income growth, -14.05%, showcases bottom-line expansion, and the EPS growth, -99.92%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth85.90%
Gross Profit Growth92.56%
EBIT Growth-14.75%
Operating Income Growth-14.75%
Net Income Growth-14.05%
EPS Growth-99.92%
EPS Diluted Growth-99.92%
Weighted Average Shares Growth102034.69%
Weighted Average Shares Diluted Growth102034.69%
Operating Cash Flow Growth23.74%
Free Cash Flow Growth23.57%
5-Year Revenue Growth per Share-28.14%
3-Year Revenue Growth per Share-99.69%
10-Year Operating CF Growth per Share100.58%
5-Year Operating CF Growth per Share100.50%
3-Year Operating CF Growth per Share-99.70%
10-Year Net Income Growth per Share100.23%
5-Year Net Income Growth per Share100.19%
3-Year Net Income Growth per Share-99.91%
10-Year Shareholders Equity Growth per Share-99.28%
5-Year Shareholders Equity Growth per Share-99.31%
3-Year Shareholders Equity Growth per Share-99.79%
Receivables Growth412.64%
Inventory Growth129.89%
Asset Growth25.15%
Book Value per Share Growth-99.87%
Debt Growth-18.13%
R&D Expense Growth370.72%
SGA Expenses Growth129.81%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,652,483,362.16, captures the company's total value, considering both debt and equity. Income quality, 2.01, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.12, gauges operational efficiency, while the research and development to revenue, 23.39%, highlights investment in innovation. The ratio of intangibles to total assets, 41.12%, indicates the value of non-physical assets, and capex to operating cash flow, -138.25%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value1,652,483,362.16
Income Quality2.01
Sales General and Administrative to Revenue0.12
Research and Development to Revenue23.39%
Intangibles to Total Assets41.12%
Capex to Operating Cash Flow-138.25%
Capex to Revenue-49.85%
Capex to Depreciation-598.99%
Stock-Based Compensation to Revenue3.58%
Graham Number7.43
Return on Tangible Assets25.70%
Graham Net Net0.96
Working Capital143,266,000
Tangible Asset Value193,832,000
Net Current Asset Value135,303,000
Average Receivables31,976,500
Average Payables9,385,000
Average Inventory11,224,500
Days Sales Outstanding49
Days Payables Outstanding64
Days of Inventory On Hand68
ROIC16.76%
ROE0.18%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.26, and the price to book ratio, 3.26, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.48, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 38.58, and price to operating cash flows, 11.18, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.26
Price to Book Ratio3.26
Price to Sales Ratio4.48
Price Cash Flow Ratio11.18
Price Earnings to Growth Ratio-0.77
Enterprise Value Multiple20.57
Price Fair Value3.26
Price to Operating Cash Flow Ratio11.18
Price to Free Cash Flows Ratio38.58
Price to Tangible Book Ratio4.61
Enterprise Value to Sales4.15
Enterprise Value Over EBITDA13.78
EV to Operating Cash Flow11.51
Earnings Yield4.00%
Free Cash Flow Yield-3.07%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Catalyst Pharmaceuticals, Inc. (CPRX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 28.073 in 2024.

What is the ticker symbol of Catalyst Pharmaceuticals, Inc. stock?

The ticker symbol of Catalyst Pharmaceuticals, Inc. stock is CPRX.

What is company IPO date?

IPO date of Catalyst Pharmaceuticals, Inc. is 2006-11-08.

What is company current share price?

Current share price is 15.650 USD.

What is stock market cap today?

The market cap of stock today is 1844555950.000.

What is PEG ratio in 2024?

The current -0.772 is -0.772 in 2024.

What is the number of employees in 2024?

In 2024 the company has 167.